other material
confidence high
sentiment positive
materiality 0.80
Altimmune reports positive Week 24 interim data from Phase 2 obesity trial; pemvidutide up to 10.7% mean weight loss
Altimmune, Inc.
- Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24; p < 0.001 vs placebo.
- In subjects ≤115 kg baseline (75% of cohort), mean weight loss reached 11.9% at 2.4 mg dose.
- ~50% achieved ≥10% weight loss and ~20% achieved ≥15% at 1.8 mg and 2.4 mg doses.
- Phase 1b diabetes trial: 7.7% mean weight loss at 2.4 mg dose; no SAEs or discontinuations.
- GI AEs mostly mild/moderate; lower doses used without titration; one SAE at 2.4 mg (nausea/vomiting).